Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Emoclot
- Development stage
- Phase 4
- Lead developer
- Kedrion
- Modality
- Blood Coagulation Factors → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
**Emoclot** is a Kedrion plasma-derived human coagulation factor VIII concentrate that contains von Willebrand factor. It is administered intravenously as replacement therapy to raise circulating factor VIII activity, control or prevent bleeding in congenital hemophilia A, and has been studied for immune-tolerance induction in hemophilia A patients with factor VIII inhibitors. ([rxreasoner.com](https://www.rxreasoner.com/monographs/emoclot))
- Brand names
- Emoclot
- Other names
- Plasma-derived FVIII/VWF concentrateFVIII/VWF complex concentrate
02
Targets
Coagulation Factor IXaPhospholipid membrane surfaceBB-031 (Von Willebrand factor)F9 (Coagulation Factor IX)F10 (Factor Xa)
Beyond the preview
Go deeper on Emoclot.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Emoclot.